Science News
from research organizations

80 percent of cervical cancers found to be preventable with latest 9-valent HPV vaccine

Date:
May 11, 2015
Source:
Cedars-Sinai Medical Center
Summary:
The new 9-valent human papillomavirus vaccine, can potentially prevent 80 percent of cervical cancers in the United States, if given to all 11- or 12-year-old children before they are exposed to the virus. The study also found the 9-Valent vaccine, under the trademark of Gardasil-9, has the potential to protect against an additional 8 percent of oropharyngeal cancers, which include the base of the tongue and tonsils. This disease is the second-most-common HPV-associated cancer.
Share:
FULL STORY

In addition to protecting against 80 percent of cervical cancers, the new 9-Valent human papillomavirus vaccine, which includes seven cancer causing HPV-types, has the potential to protect against nearly 19,000 other cancers diagnosed in the United States, including anal, oropharyngeal and penile cancers.
Credit: © Barabas Attila / Fotolia

The new 9-valent human papillomavirus vaccine, can potentially prevent 80 percent of cervical cancers in the United States, if given to all 11- or 12-year-old children before they are exposed to the virus.

In addition to protecting against 80 percent of cervical cancers, the new 9-Valent human papillomavirus vaccine, which includes seven cancer causing HPV-types -- 16,18,31,33,45,52 and 58 -- has the potential to protect against nearly 19,000 other cancers diagnosed in the United States, including anal, oropharyngeal and penile cancers. This is a 13 percent increase in protection against HPV-related cancers in comparison to the first vaccines on the market, Gardasil and Cervarix, which protected against HPV types 16 and 18.

These findings come from a seven-center study published in the Journal of the National Cancer Institute. The Centers for Disease Control and Prevention initiated the research effort, in conjunction with Cedars-Sinai.

"This is the first comprehensive study of its kind and shows the potential to not only reduce the global cancer burden, but also guide clinical decision-making with regard to childhood vaccinations," said Marc T. Goodman, PhD, MPH, senior author of the study and director of Cancer Prevention and Genetics at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute.

The study found the 9-Valent vaccine, under the trademark of Gardasil-9, also has the potential to protect against an additional 8 percent of oropharyngeal cancers, which include the base of the tongue and tonsils. This disease is the second-most-common HPV-associated cancer.

"We found that 70 percent of patient DNA tissue samples with cancer of the oropharynx harbored HPV," added Goodman. "This is a much higher percentage of HPV than observed in other studies, likely because of changes in sexual behaviors, such as increased oral-genital contact."

The 9-Valent vaccine was also found to potentially increase protection from other HPV-related cancers including those of the vulva, from 71 to 92 percent; vagina, from 73 percent to 98 percent; the penis, 76 percent to 90 percent; and the anus, 87 percent to 96 percent.

To compile these data, researchers examined 2,670 HPV DNA tissue samples from seven population-based cancer registries.

Study authors intend to perform additional research in the future to follow up on their estimate of how well the current vaccines protect against HPV-associated cancers.


Story Source:

Materials provided by Cedars-Sinai Medical Center. Note: Content may be edited for style and length.


Journal Reference:

  1. M. Saraiya, E. R. Unger, T. D. Thompson, C. F. Lynch, B. Y. Hernandez, C. W. Lyu, M. Steinau, M. Watson, E. J. Wilkinson, C. Hopenhayn, G. Copeland, W. Cozen, E. S. Peters, Y. Huang, M. S. Saber, S. Altekruse, M. T. Goodman. US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines. JNCI Journal of the National Cancer Institute, 2015; 107 (6): djv086 DOI: 10.1093/jnci/djv086

Cite This Page:

Cedars-Sinai Medical Center. "80 percent of cervical cancers found to be preventable with latest 9-valent HPV vaccine." ScienceDaily. ScienceDaily, 11 May 2015. <www.sciencedaily.com/releases/2015/05/150511163018.htm>.
Cedars-Sinai Medical Center. (2015, May 11). 80 percent of cervical cancers found to be preventable with latest 9-valent HPV vaccine. ScienceDaily. Retrieved May 25, 2017 from www.sciencedaily.com/releases/2015/05/150511163018.htm
Cedars-Sinai Medical Center. "80 percent of cervical cancers found to be preventable with latest 9-valent HPV vaccine." ScienceDaily. www.sciencedaily.com/releases/2015/05/150511163018.htm (accessed May 25, 2017).

RELATED STORIES